Tracker wrote:Packo wrote:
Few weeks ago I contacted Prof. Slavin, he let me know that the CTCI team is now able to (in the laboratory) trans-differentiate bone marrow and adipose tissue derived mesenchymal stromal stem cells (MSC) to neural stem cells, motor neurons, dopaminergic neurons, astrocytes and oligodendrocytes that can produce myelin, and therefore he believes it may be possible to use such methods to induce re-myelination in patients with multiple sclerosis. They need to do animal studies to confirm the efficacy of their new patented procedure before they can get approval to apply that methods clinically. He also stated that adipose tissue derived mesenchymal stromal stem cells seem to develop much faster and much nicer as compared with bone marrow derived stem cells but they do not yet know which source of MSCs is more effective clinically.
The future looks bright!
Professor Slavin told me that to do the animal studies, they need funding of approx USD$2-3million. When they have the funding, the studies will be done, and if proven, clinical application will begin immediately.
Anyone got ideas how to raise the funds?
Do you know how much this procedure would be different from NurOwn tested clinically at Hadassah? Did he mention anything about potential timing?
I just received an answer from prof Slavin and he said that he thinks colony expanded MSC treatment is safe. He also said that his experience is that 60-70% of the patients benefit from that. They apply circa 1-2 million MSC per body kilogram. Most of the MSCs are applied intrathecal while the rest IV. He was a pioneer of this treatment. He played a key role in developping this protocol at Hadassah. Most of the ongoing clinical trials with MSCs just follow his footsteps and try to replicate his findings. In the meantime, he is over many treatments.
As for the clinical trials where they completed phase 1 at Hadassah, 11 patients out of 15 showed improvement in EDSS. The average improvement of these patients was 1,2 in EDSS in 6 months. No one showed deterioration in EDSS in tha same period. He also told me that the sooner you get any treatment the more you can benefit from that.
As for replicating his results, in the UK they plan to finish phase 2 in 5 years with 150 patients. Then, will just phase 3 start. So, offical results will come out probably in 10 years.
I also talked to an academist in this field, who has no ties to any clinics profiting from this treatment, and he said that he thinks MSC is fairly safe and he would take part in such a clinical trial if he had MS.
I am just wondering how Celltex's adipose tissue derived treatment compares to this. They claim that they inject 600 million MSCs vs. circa 150 million MSCs applied in other places. Their treatment is IRB reviewed. Anyone knows about IRB reviewed treatments? How safe are they?